Mark Jeffrey Delong
Chief Business & Strat Officer · 5 filings · Latest: May 14, 2026
Apellis Pharmaceuticals, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
APLS | Mark Jeffrey Delong | Chief Business & Strat Officer | Feb 11, 2026 | Sale | $22.15 | 368 | $8.2K | 114,591 | |
APLS | DeLong Mark Jeffrey | — | Feb 11, 2026 | Proposed Sale | $22.15 | 368 | $8.2K | — | |
APLS | Mark Jeffrey Delong | Chief Business & Strat Officer | Jan 22, 2026 | Sale | $21.77 | 3,371 | $73.4K | 78,353 | |
APLS | DeLong Mark Jeffrey | — | Jan 22, 2026 | Proposed Sale | $21.77 | 3,371 | $73.4K | — | |
APLS | Mark Jeffrey Delong | Chief Business & Strat Officer | Jan 20, 2026 | Sale | $19.79 | 1,334 | $26.4K | 81,724 | |
APLS | DeLong Mark Jeffrey | — | Jan 20, 2026 | Proposed Sale | $19.79 | 1,334 | $26.4K | — | |
APLS | DeLong Mark Jeffrey | — | Jan 13, 2026 | Proposed Sale | $22.19 | 1,780 | $39.5K | — | |
APLS | DeLong Mark Jeffrey | — | Feb 11, 2025 | Proposed Sale | $28.54 | 363 | $10.4K | — | |
APLS | DeLong Mark Jeffrey | — | Jan 29, 2025 | Proposed Sale | $29.52 | 365 | $10.8K | — | |
APLS | DeLong Mark Jeffrey | — | Jan 22, 2025 | Proposed Sale | $30.43 | 1,396 | $42.5K | — | |
APLS | DeLong Mark Jeffrey | — | Jan 17, 2025 | Proposed Sale | $29.96 | 1,235 | $37.0K | — | |
APLS | DeLong Mark Jeffrey | — | Jan 13, 2025 | Proposed Sale | $28.70 | 1,627 | $46.7K | — |